Proceedings of the 13th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026
Vol. 5 No. s1 (2026)
The therapeutic landscape of cancer-associated splanchnic vein thrombosis
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 16 April 2026
298
Views
145
Downloads
Authors
Splanchnic vein thrombosis (SVT), including portal, splenic, and mesenteric vein thrombosis and the Budd–Chiari syndrome, is an uncommon manifestation of venous thromboembolism frequently associated with solid abdominal malignancies and myeloproliferative neoplasms (MPNs). The management of cancer-associated SVT is challenging due to heterogeneous clinical presentations, competing risks of thrombosis and bleeding, and the lack of high-quality clinical studies in this setting. Based on available evidence, anticoagulation is associated with higher rates of recanalization in patients with solid cancer, with no impact on the mortality rates and a non-negligible bleeding risk. Most available data derive from observational studies, with low-molecular-weight heparin (LMWH) historically representing the most frequently used anticoagulant, although direct oral anticoagulants (DOACs) are increasingly prescribed following evidence from cancer-associated thrombosis in usual sites. In MPN-associated SVT, anticoagulation is generally recommended indefinitely in combination with cytoreductive therapy. Available cohort studies suggest comparable outcomes among vitamin K antagonists (VKAs), LMWH, and DOACs, but robust comparative data are lacking. Overall, current evidence supports an individualized, risk-adapted anticoagulant approach in patients with cancer-associated SVT.
Downloads
Download data is not yet available.
Citations
1. Ageno W, Dentali F, Pomero F, et al. Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari syndrome. Thromb Haemost 2017;117:794–800. DOI: https://doi.org/10.1160/TH16-10-0781
2. Søgaard KK, Darvalics B, Horváth-Puhó E, Sørensen HT. Survival after splanchnic vein thrombosis: A 20-year nationwide cohort study. Thromb Res 2016;141:1–7. DOI: https://doi.org/10.1016/j.thromres.2016.02.024
3. Cardi S, Wolf S, Fumagalli RM, et al. Splanchnic vein thrombosis (2003-2022): a Swiss nationwide epidemiological study. Thromb Res 2025;250:109319. DOI: https://doi.org/10.1016/j.thromres.2025.109319
4. Ageno W, Riva N, Schulman S, et al. Long-term clinical outcomes of splanchnic vein thrombosis results of an international registry. JAMA Intern Med 2015;175:1474-80. DOI: https://doi.org/10.1001/jamainternmed.2015.3184
5. Thatipelli MR, McBane RD, Hodge DO, Wysokinski WE. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol 2010;8;200-5. DOI: https://doi.org/10.1016/j.cgh.2009.09.019
6. Garcia-Pagán JC, Valla DC. Primary Budd-Chiari syndrome. N Engl J Med 2023;388:1307-16. DOI: https://doi.org/10.1056/NEJMra2207738
7. Smalberg JH, Arrends LR, Valla DC, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood 2012;120:4921-28. DOI: https://doi.org/10.1182/blood-2011-09-376517
8. Qi X, Yang Z, Bai M, et al. Meta-analysis: The significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis. Aliment Pharmacol Ther 2011;33:1087-103. DOI: https://doi.org/10.1111/j.1365-2036.2011.04627.x
9. Poisson J, Plessier A, Kiladjian JJ, et al. Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. J Hepatol 2017;67:501-7. DOI: https://doi.org/10.1016/j.jhep.2017.04.021
10. Li M, Deb Stefano V, Song T, et al. Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis. Thromb Res 2018;167:96-103. DOI: https://doi.org/10.1016/j.thromres.2018.05.007
11. Søgaard KK, Farkas DK, Pedersen L, Sørensen HT. Splanchnic venous thrombosis is a marker of cancer and a prognostic factor for cancer survival. Blood 2015;126:957-63. DOI: https://doi.org/10.1182/blood-2015-03-631119
12. Valeriani E, Di Nisio M, Riva N, et al. Clinical history of cancer-associated splanchnic vein thrombosis. J Thromb Haemost 2021;19:983-91. DOI: https://doi.org/10.1111/jth.15214
13. Mulder FI, Bosch FTM, Young AM, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood 2020;136:1433-41. DOI: https://doi.org/10.1182/blood.2020005819
14. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7-30. DOI: https://doi.org/10.3322/caac.21442
15. Ageno W, Riva N, Schulman S, et al. Antithrombotic treatment of splanchnic vein thrombosis: Results of an international registry. Semin Thromb Hemost 2014;40:99-105. DOI: https://doi.org/10.1055/s-0033-1363473
16. Garcia-Villa A, Criado-Álvarez JJ, Carnevali M, et al. Anticoagulant therapy for cancer-associated splanchnic vein thrombosis: Outcomes during a one-year follow-up period. Thromb Res 2025;253:109411. DOI: https://doi.org/10.1016/j.thromres.2025.109411
17. Hui S, Zeid K, Kou R, et al. Management and outcomes in patients with tumor thrombus: a retrospective cohort study. J Thromb Haemost 2025;23:201-9. DOI: https://doi.org/10.1016/j.jtha.2024.10.002
18. Samuelson Bannow BR, Lee AYY, Khorana AA, et al. Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review. Res Pract Thromb Haemost 2018;2:664-9. DOI: https://doi.org/10.1002/rth2.12111
19. Andersen M, Jr, Fernandez Turizo MJ, Dodge LE, et al. Impact of thrombocytopenia on bleeding and thrombotic outcomes in adults with cancer-associated splanchnic vein thrombosis. Blood Adv 2024;8:6151-60. DOI: https://doi.org/10.1182/bloodadvances.2024014249
20. Afzal A, Suhong L, Gage BF, et al. Splanchnic vein thrombosis predicts worse survival in patients with advanced pancreatic cancer. Thromb Res 2020;185:125-31. DOI: https://doi.org/10.1016/j.thromres.2019.11.023
21. Candeloro M, Valeriani E, Monreal M, et al. Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis. Blood Adv 2022;6:4516-23. DOI: https://doi.org/10.1182/bloodadvances.2022007961
22. Shang H, Jiang JY, Guffey D, et al. Natural history of cancer-associated splanchnic vein thrombosis. J Thromb Haemost 22024;2:1421-32. DOI: https://doi.org/10.1016/j.jtha.2024.01.019
23. Plessier A, Darwish-Murad S, Hernandez-Guerra M, et al. Acute portal vein thrombosis unrelated to cirrhosis: a prospective multicenter follow-up study. Hepatology 2010;51:210-8. DOI: https://doi.org/10.1002/hep.23259
24. Condat B, Pessione F, Denninger MH, et al. Recent portal or mesenteric venous thrombosis: Increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000;32:466-70. DOI: https://doi.org/10.1053/jhep.2000.16597
25. Ageno W, Westendord JB, Contino L, et al. Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study. Blood Adv 2022;6:3569-78. DOI: https://doi.org/10.1182/bloodadvances.2022007397
26. Arber DA, Orazi A, Hasserjian R. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;128:462-3. DOI: https://doi.org/10.1182/blood-2016-06-721662
27. Arber DA, Orazi A, Hasserjian RP. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022;140:1200-28. DOI: https://doi.org/10.1182/blood.2022015850
28. Falanga A, Marchetti M, Schieppati F. Prevention and management of thrombosis in BCR/ABL-negative myeloproliferative neoplasms. Hamostaseologie 2021;41:48-57. DOI: https://doi.org/10.1055/a-1334-3259
29. Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: A international study. J Clin Oncol 2011;29:3179-84. DOI: https://doi.org/10.1200/JCO.2010.34.5298
30. Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010;4:778-82. DOI: https://doi.org/10.1182/blood-2009-08-238956
31. Barbui T, Carobbio A, Rumi E. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood 2014;124:3021-3. DOI: https://doi.org/10.1182/blood-2014-07-591610
32. Sekhar M, Mcvinnie K, Burroughs AK. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol 2013;162:730-47. DOI: https://doi.org/10.1111/bjh.12461
33. Kiladjian JJ, Cassinat B. Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies. Am J Hematol 2023;98:794-800. DOI: https://doi.org/10.1002/ajh.26896
34. Tefferi A, Rumi E, Ginazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia 2013;27:1874-81. DOI: https://doi.org/10.1038/leu.2013.163
35. Morsia E, Ranalli P, Baldoni S, et al. Genetic insights into myeloproliferative neoplasms and unusual sites thrombosis. Ann Hematol 2025;104:4525-9. DOI: https://doi.org/10.1007/s00277-025-06606-5
36. Galante A, De Gottardi A. Portal vein thrombosis: An overview of current treatment options. Acta Gastroenterol Belg 2021;84:327-32. DOI: https://doi.org/10.51821/84.2.327
37. Jara-Palomares L, Marin-Barrera L, Giraldez-Gallego A, et al. Clinically relevant bleeding and thrombotic events in non-cirrhotic splanchnic vein thrombosis. Long-term follow up. Thromb Res 2017;154:55-8. DOI: https://doi.org/10.1016/j.thromres.2017.03.028
38. Valeriani E, et al. Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis. Blood 2021;137:1233-40. DOI: https://doi.org/10.1182/blood.2020006827
39. Elkrief L, Payancé A, Plessier A, et al. Management of splanchnic vein thrombosis. JHEP Reports 2023;5:100667. DOI: https://doi.org/10.1016/j.jhepr.2022.100667
40. de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII – Renewing consensus in portal hypertension. J Hepatol 2022;76:959-74. DOI: https://doi.org/10.1007/978-3-031-08552-9
41. Castelli R, Gallipoli P, Schiavon R, et al. High prevalence of heparin induced thrombocytopenia with thrombosis among patients with essential thrombocytemia carrying V617F mutation. J Thromb Thrombolysis 2018;45:106-13. DOI: https://doi.org/10.1007/s11239-017-1566-1
42. Plessier A, Sibert A, Consigny Y, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology 2006;44:1308-16. DOI: https://doi.org/10.1002/hep.21354
43. Randi ML, Tezza F, Scapin M, et al. Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis. Acta Haematol 2010;123:140-5. DOI: https://doi.org/10.1159/000280466
44. Zaman S, Wiebe S, Bernal W, et al. Increased prevalence of heparin-induced thrombocytopenia in patients with Budd-Chiari syndrome: a retrospective analysis. Eur J Gastroenterol Hepatol 2016;28:967-71. DOI: https://doi.org/10.1097/MEG.0000000000000632
45. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141:e419S-e496S. DOI: https://doi.org/10.1378/chest.11-2301
46. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378:615-24. DOI: https://doi.org/10.1056/NEJMoa1711948
47. Raskob GE,van Es N, Segers A, et al. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol 2016;3:e379-87. DOI: https://doi.org/10.1016/S2352-3026(16)30057-6
48. Andersen M, Jr, Shang H, Fernandez Turizo MJJ, et al. Anticoagulation and major bleeding or recurrent thrombosis in patients with isolated cancer-associated splanchnic vein thrombosis: a multi-center cohort study. Blood 2024;144:1247. DOI: https://doi.org/10.1182/blood-2024-201064
49. Di Nisio M, Valeriani E, Riva N, et al. Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation. J Thromb Haemost 2020;8:1562-8. DOI: https://doi.org/10.1111/jth.14836
50. How CJ, Chrysafi P, Ko A, et al. Anticoagulation management of splanchnic vein thrombosis in myeloproliferative neoplasms: a global abdominal/splanchnic thrombosis retrospective observational study in 486 MPN patients (GASTRO-MPN). Blood 2024;144:16. DOI: https://doi.org/10.1182/blood-2024-199107
51. Ko A, Milana L, Riva N, et al. Splanchnic vein thrombosis with and without myeloproliferative neoplasms: a comparative cohort study. Proceedings EHA2025, Abstract S322.
52. Sant’Antonio E, Guglielmelli P, Pieri L, et al. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. Am J Hematol 2020;95:156-66. DOI: https://doi.org/10.1002/ajh.25677
53. Mahé I, Carrier M, Mayeur D, et al. Extended reduced-dose apixaban for cancer-associated venous thromboembolism. N Engl J Med 2025;392:1363-73. DOI: https://doi.org/10.1056/NEJMoa2416112
54. Lyman GH, Carrier M, Ay C, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021;5:927-74. DOI: https://doi.org/10.1182/bloodadvances.2021004734
55. Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Onco 2023;41:3063-71. DOI: https://doi.org/10.1200/JCO.23.00294
56. Streiff MB, Holmstrom B, Angelini D, et al. Cancer-associated venous thromboembolic disease, Version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2024;22:483-506. DOI: https://doi.org/10.6004/jnccn.2024.0046
57. Rautou PE, Moga L, Hernandez-Gea V, et al. EASL Clinical Practice Guidelines on vascular diseases of the liver. J Hepatol 2025;84:399-456. DOI: https://doi.org/10.1016/j.jhep.2025.08.001
58. Northup PG, Garcia-Pagan JC, Garcia-Tsao G, et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;73:366-413. DOI: https://doi.org/10.1002/hep.31646
How to Cite
1.
Abenante A, Catalani F, Ageno W. The therapeutic landscape of cancer-associated splanchnic vein thrombosis. Bleeding Thromb Vasc Biol [Internet]. 2026 Apr. 16 [cited 2026 Oct. 18];5(s1). Available from: https://www.btvb.org/btvb/article/view/458
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
